Oncology
Clinical research is centered on advanced solid tumors, with attention to cancers that are locally advanced or metastatic and carry specific molecular alterations.
- Solid tumor malignancies
- Metastatic cancer
- Locally advanced cancer
The sponsor’s research activity in this area reflects a focus on targeted treatment strategies for difficult-to-treat tumor populations.
TP53-mutated cancer
Its clinical interest includes tumors with a TP53 Y220C mutation, a defined molecular subtype within p53-altered cancers.
- TP53 Y220C mutation
- p53 pathway abnormalities
- Mutation-defined oncology
This area highlights a precision medicine focus on cancers selected by a specific genomic feature.
Precision oncology
Research activity is directed toward molecularly targeted cancer therapy in patients whose tumors are identified by a distinct genetic profile.
- Biomarker-defined patient selection
- Targeted anticancer therapy
- Genomic oncology
The sponsor’s interests align with therapeutic development for mutation-specific disease subsets in oncology.
